ProtAffin Biotechnologie AG

ProtAffin Biotechnologie AG is a pre-clinical biotechnology company based in Graz, Austria.

We focus on developing novel biotechnology products for acute and chronic inflammatory diseases. We are leaders in the field of protein-glycan interactions, which are increasingly recognised as driving a number of inflammatory as well as many other pathological processes.

ProtAffin has developed the CellJammer™ discovery technology to develop protein-based products which interfere with protein-glycosaminoglycan (GAG) interactions. Our lead product PA401 was derived from our platform technology and is based on the pro-inflammatory human chemokine interleukin-8 (IL-8). PA401 is in pre-clinical development and shows in vivo activity in a number of acute and chronic inflammatory disease models.

ProtAffin’s unique approach to targeting protein-GAG interactions has advantages to competitor approaches, such as monoclonal antibodies or GAG mimetics, to therapeutically interfere at this interaction site.